Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

DISEASE CHARACTERISTICS: Diagnosis of any of the following malignant gliomas: Glioblastoma multiforme Anaplastic astrocytoma Grade 3 or greater WHO astrocytic, oligodendroglial, or mixed glial tumors that were initially diagnosed by histologic examination of a tumor specimen obtained from biopsy or resection Recurrent disease No more than 3 prior recurrences Measurable recurrent or residual primary CNS neoplasm on contrast-enhanced MRI or CT scan No evidence of CNS hemorrhage on baseline MRI or CT scan PATIENT CHARACTERISTICS: Karnofsky performance status 60-100% Hematocrit > 29% Absolute neutrophil count > 1,500/mm³ Platelet count > 125,000/mm³ Creatinine < 1.5 mg/dL SGOT < 1.5 times upper limit of normal (ULN) Bilirubin < 1.5 times ULN Not pregnant or nursing Fertile patients must use effective contraception No active infection No significant traumatic injury within the past 28 days PRIOR CONCURRENT THERAPY: At least 6 weeks since prior surgical resection More than 28 days since prior major surgical procedure or open biopsy More than 7 days since prior minor surgical procedure, fine-needle aspirations, or core biopsies At least 6 weeks since prior chemotherapy* At least 4 weeks since prior radiotherapy* No concurrent immunosuppressive agents No concurrent therapeutic anticoagulation Concurrent corticosteroids allowed if dose has been stable for 1 week prior to study entry NOTE: * Unless there is unequivocal evidence of progressive disease